Myriad Genetics Inc. (MYGN)

Oncology Corporate Profile

Stock Performance


HQ Location

320 Wakara Way
Salt Lake City, UT 84108

Company Description

Myriad Genetics is a leading healthcare company focused on the development and marketing of novel molecular diagnostic products.


Brand Generic Indication
BRACAnalysis®N/AA genetic test for hereditary breast and ovarian cancer.
Colaris AP®N/AA genetic test for adenomatous polyposis syndromes.
Colaris® (genetic testing for hereditary cancer)N/AA genetic test for hereditary nonpolyposis colorectal cancer (HNPCC).
Melaris®N/AA genetic test for hereditary melanoma.
Prolaris®diagnosticProlaris® has been proven to predict disease specific mortality in prostate cancer patients following needle biopsy. In a study of men with conservatively managed, localized prostate cancer, with an end point of disease specific mortality, Prolaris® was predictive of disease aggressiveness. Prolaris® testing is also particularly well-suited for post-prostatectomy patients to better estimate the risk of biochemical recurrence (BCR).
TheraGuide 5-FU®N/AA genetic test to predict toxicity to 5-FU/capecitabine-based chemotherapy.

View additional information on commercial products here »

This company does not have any pipeline products


Recent News Headlines

Myriad's BRACAnalysis CDx® Test Identifies Patients with Ovarian Cancer Who Would Benefit From Second-Line Maintenance Treatment with Olaparib

10/26/2016 04:41 pm

(Myriad Genetics) Oct 26, 2016 - Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, today announced that its BRACAnalysis CDx® test accurately identified patients who may benefit from treatment with olaparib. The BRACAnalysis CDx test was included in the SOLO2 study (NCT01874353) as a diagnostic with olaparib, an oral PARP inhibitor being developed by AstraZeneca.

Myriad Genetics Inc. Forms Relationship with ION Solutions to Deliver Quality Hereditary Cancer Tests and Services to the Nation's Largest Network of Community Oncologists

10/21/2016 05:16 pm

(Myriad) Oct 21, 2016 - Myriad Genetics, Inc., a global leader in personalized medicine, and ION Solutions, a part of AmerisourceBergen, and the largest physician services organization specializing in the support of community oncology, announced today that they have entered into a relationship to deliver quality hereditary cancer test results and services to ION member practices.

Myriad’s myChoice® HRD Test Identifies Patients with Ovarian Cancer Who May Benefit from Treatment with Niraparib

10/10/2016 03:21 pm

(Yahoo! Finance) Oct 8, 2016 - Myriad Genetics, Inc, a leader in molecular diagnostics and personalized medicine, today announced that its myChoice® HRD test identified more than double the number of patients who may benefit from treatment with niraparib than were identified by germline BRCA testing alone.

The US Oncology Network Selects Myriad Genetics as Preferred Provider for Hereditary Cancer Testing

10/4/2016 05:33 pm

(4-traders) Oct 4, 2016 - Myriad Genetics, Inc. and The US Oncology Network announced today that The Network has selected Myriad Genetic Laboratories as its preferred provider laboratory for hereditary cancer testing.

Scientists Work To Protect The Kidneys From Powerful Cancer Drug

6/15/2016 11:05 am

(Jagwire/Augusta University) June 13, 2016 - Researchers want to turn the tide by protecting the kidneys while improving cisplatin’s efficacy against cancer.

Improved Survival For Adult Acute Lymphoblastic Leukaemia (All) Patients

6/13/2016 12:00 pm

(EHA 2016) June 11, 2016 - Historical survival for patients 18-45 years with ALL is approximately 40%. However the event free survival for ALL patients 18-45 years has improved to 73% following implementation of the NOPHO ALL2008 protocol in July 2008.

Myriad On Genetic Testing For Cancer Risk: Insurance Gap Is A ‘Crisis'

6/6/2016 07:22 pm

(Forbes) June 6, 2016 - Myriad is among several companies that are facing a headwind of resistance from, among others, the insurance industry, which has doubts about the value of testing so many genes.

Myriad Will Present Three New Hereditary Cancer Studies at the ASCO Annual Meeting

6/5/2016 11:27 pm

(Benzinga) June 5, 2016 - Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, today announced that results from three studies with the Myriad myRisk® Hereditary Cancer test will be featured in podium presentations at the 2016 American Society of Clinical Oncology annual meeting.

Sunday at ASCO: Plenary Shows Progress in Myeloma

6/5/2016 06:00 pm

(Medscape Medical News) June 5, 2016 - Among the best clinical data selected for the plenary session is the CASTOR study, showing impressive progression-free survival in multiple myeloma.

FDA OKs First Liquid Biopsy for Lung Cancer Mutation

6/2/2016 11:03 am

(Medscape Medical News) June 1, 2016 - The US Food and Drug Administration (FDA) today approved the first blood-based genetic test that can detect epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer patients.

Myriad Acquires Sividon Diagnostics

6/1/2016 04:48 pm

(StreetInsider) May 31, 2016 - Strengthens market leading oncology product portfolio with breast cancer prognostic test EndoPredict®.

Myriad Genetics' Statement on HIPAA Complaint from Four Patients

5/20/2016 04:42 pm

(Myriad) May 19, 2016 - Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, today announced a complaint was filed against the Company with the Department of Health and Human Services on behalf of four individuals seeking their genetic testing results.

Patients Challenge Myriad Genetics for Access to Their Gene Data

5/20/2016 04:33 pm

(STAT) May 19, 2016 - Genetic testing company Myriad Genetics, the defendant in a landmark Supreme Court case over gene patents, is back in the spotlight — this time, for withholding genetic data from patients.

Myriad Hit With Complaint Over Access to Genetic Information

5/20/2016 11:49 am

(Reuters) May 19, 2016 - The American Civil Liberties Union on Thursday filed a complaint with the federal government accusing genetic testing company Myriad Genetics Inc of refusing to provide four patients with personal genetic information they requested, though the company has now provided it.

Myriad Genetics : Announces Plans to Launch a Web Portal for Patients that Will Provide Access to Test Results, Tools and Health Information

5/19/2016 05:55 pm

(4-traders) May 18, 2016 - Myriad Genetics, Inc. today announced plans to launch a new web portal on that will allow patients to access their personal test results as well as other high-quality tools and ideas to help them make healthcare decisions.

Myriad to Present New Research at the 2016 ASCO Annual Meeting

5/19/2016 05:34 pm

(NASDAQ) May 18, 2016 - Data demonstrate expanded utility of the MyRisk® hereditary cancer test.

Myriad Expands Diagnostic Research Collaboration with TESARO and Merck

2/22/2016 05:45 pm

(EconoTimes) Feb 22, 2016 – Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, today announced a strategic research collaboration with TESARO and Merck, known as MSD outside the U.S. and Canada, to help identify potential responders to an investigational combination drug therapy using TESARO's PARP inhibitor (niraparib) plus KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy.

FDA Expands Label for Palbociclib (Ibrance) in Metastatic Breast Cancer

2/22/2016 01:00 pm

(Managed Care magazine) Feb 22, 2016 - The FDA has approved a new indication expanding the use of palbociclib (Ibrance, Pfizer) 125-mg capsules, a therapy for metastatic breast cancer.

Durvalumab Granted Breakthrough Therapy Designation by US FDA for Treatment of Patients With PD-L1 Positive Urothelial Bladder Cancer

2/17/2016 07:01 am

(AstraZeneca) Feb 17, 2016 - AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) for durvalumab (MEDI4736), an investigational human monoclonal antibody directed against programmed death ligand-1 (PD-L1), for the treatment of patients with PD-L1 positive inoperable or metastatic urothelial bladder cancer whose tumour has progressed during or after one standard platinum-based regimen.

Gene Previously Observed Only in Brain is Important Driver of Metastatic Breast Cancer

2/12/2016 11:04 am

(The Wistar Institute) Feb 12, 2016 - Scientists from The Wistar Institute have shown that one gene that was once thought only to be found in the brain is also expressed in breast cancer and helps promote the growth and spread of the disease.

MabVax Therapeutics Receives FDA Authorization for Phase I Clinical Trial with 89Zr-HuMab-5B1 as PET Imaging Agent for Pancreatic Cancer

2/2/2016 12:01 pm

(TheStreet) Feb 2, 2016 - MabVax Therapeutics Holdings, Inc. announces receipt of notice from the U.S. Food and Drug Administration (FDA) authorizing initiation of a Phase I clinical trial with 89Zr-HuMab-5B1 as a new generation PET scan cancer imaging agent in patients with pancreatic cancer.

Insurer’s Approval Of Genetic Testing For Some Cancers Raises Questions

2/2/2016 12:00 pm

(Kaiser Health News) Feb 2, 2016 - Pennsylvania-based Independence Blue Cross’ announcement that it will cover a complex type of genetic testing for some cancer patients thrusts the insurer into an ongoing debate about how to handle an increasing array of these expensive tests.

Myriad Advances Prostate and Renal Cancer Molecular Diagnostic Tests at the 2016 ASCO Genitourinary Cancers Symposium

1/7/2016 05:38 pm

(Yahoo! Finance) Jan 7, 2016 - Prolaris identifies 80 percent more prostate cancer patients eligible for active surveillance.

Multiple Scientific Presentations at the San Antonio Breast Cancer Symposium Highlight the Clinical Utility of the Myriad myRisk™ Hereditary Cancer Gene Panel Test

12/9/2015 07:34 pm

(StreetInsider) Dec 9, 2015 - Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, today announced it will highlight three scientific presentations related to its myRisk Hereditary Cancer test at the 2015 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas.

Myriad Genetics and Tufts Health Plan Sign Agreement to Cover Prolaris® for Members with Localized Prostate Cancer

10/7/2015 04:44 pm

(Benzinga) Oct 7, 2015 – Myriad Genetics, Inc. today announced that it has signed a three-year contract with Tufts Health Plan through which the plan will provide coverage of Prolaris® for members diagnosed with localized prostate cancer. Prolaris is the first and only biopsy test validated against prostate cancer specific mortality.

Myriad Genetics Posts Positive Data on Oncology Tests

9/29/2015 03:54 pm

(NASDAQ/ Sept 25, 2015 - Myriad Genetics Inc. recently released positive data from three new studies involving its myChoice homologous recombination deficiency (HRD) and Tumor BRACAnalysis CDx companion diagnostic tests and Prolaris Prostate cancer test.

NantWorks Enters into Exclusive License Agreement with Amgen to Target Cancer c-Met Receptor

9/14/2015 11:01 am

(Yahoo! Finance) Sept 14, 2015 - Acquires exclusive rights to a novel small molecule drug in phase 2 development for gastric and esophageal cancers.

AbbVie Announces Submission of a Supplemental New Drug Application for IMBRUVICA® (ibrutinib) for Treatment-Naive Chronic Lymphocytic Leukemia

9/14/2015 10:04 am

(StreetInsider) Sept 14, 2015 - AbbVie, a global biopharmaceutical company, announced today that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) based on the randomized, multi-center, open-label Phase III RESONATE(TM)-2 (PCYC-1115) trial assessing the use of IMBRUVICA® (ibrutinib) versus chlorambucil in treatment-naive chronic lymphocytic leukemia (CLL) patients aged 65 years or older.

ASCO Signs Joint Letter to Congress Urging Funding Relief for Discretionary Programs

9/11/2015 12:01 pm

(ASCO in Action) Sept 11, 2015 - On Sept. 10, NDD United sent a joint letter to every Member of Congress calling for halts to cuts in discretionary spending programs, including those that are nondefense discretionary (NDD).

Myriad Adds to Scientific Evidence for the myPlan® Lung Cancer Prognostic Test

9/9/2015 03:48 pm

(TheStreet) Sept 9, 2015 – Myriad Genetics, Inc. today presented two posters on its myPlan® Lung Cancer prognostic test at the International Association for the Study of Lung Cancer (IASLC) 16TH World Conference on Lung Cancer being held in Denver, Colo.

First Defendant in Fake Cancer-Drug Case to Be Arraigned

8/19/2015 11:05 am

(Wall Street Journal) Aug 18, 2015 - The first defendant will be arraigned in U.S. federal court next week in connection with an indictment involving Canada Drugs, the Winnipeg-based company accused of selling counterfeit drugs in the U.S.

Myriad Receives Favorable Medicare Final Coverage Decision for the Prolaris(R) Test

8/13/2015 05:04 pm

(Myriad) Aug 13, 2015 - Myriad Genetics, Inc. today announced that Noridian, the Medicare Administrative Contractor (MAC) for Myriad, has issued a final local coverage determination (LCD) for Prolaris®, Myriad's pioneering prognostic test for assessing the aggressiveness of prostate cancer.

Web App Helps Researchers Explore Cancer Genetics

7/24/2015 11:02 am

(Brown University) July 23, 2015 - Brown University computer scientists have developed a new interactive tool to help researchers and clinicians explore the genetic underpinnings of cancer.

Merck & Co's Keytruda Approved In EU for Melanoma

7/22/2015 12:05 pm

(PharmaTimes [UK]) July 22, 2015 - Merck & Co’s anti-PD-1 therapy Keytruda has been approved in Europe for the treatment of advanced skin cancer.

Myriad Significantly Advances the myChoice(R) HRD(TM) Companion Diagnostic Test

5/29/2015 07:28 pm

(Myriad) May 29, 2015 - Myriad Genetics, Inc. today announced new clinical studies on its myChoice HRD companion diagnostic test at the 2015 American Society of Clinical Oncology annual meeting being held in Chicago, Ill.

Myriad Presents New myRisk(TM) Hereditary Cancer Data at 2015 ASCO Annual Meeting

5/29/2015 07:27 pm

(Myriad) May 29, 2015 - Myriad Genetics, Inc. today announced it will highlight several new clinical studies on its myRisk Hereditary Cancer molecular diagnostic test at the 2015 American Society of Clinical Oncology annual meeting being held in Chicago, Ill.

Myriad Validates Active Surveillance Threshold with Prolaris® for Men with Prostate Cancer

5/15/2015 05:31 pm

(MarketWatch) May 15, 2015 - Additional data show Prolaris changed treatment plans in 48 percent of cases.

Patient Navigators Improve Cancer Screening

5/7/2015 12:00 pm

(Medscape Medical News) May 6, 2015 - For patients who do not complete screening tests for breast, cervical, and colorectal cancer, rates can be significantly increased when information technology is used to identify and target interventions, according to results from a new study.

Myriad Genetics Fights Off Threats From Rivals

5/4/2015 12:13 pm

(Wall Street Journal) May 3, 2015 - Nearly two years after the Supreme Court struck down its gene patents, Myriad is fighting to sustain its business model amid growing threats from rivals.

ImmuneXcite Presents New Preclinical Data at AACR Demonstrating Ability of Its Novel Cancer Immunotherapy Approach to Activate a Potent and Precise T-Cell Attack on Tumors

4/22/2015 11:03 am

( Apr 21, 2015 - Company’s mAbXcite platform showed significant anti-tumor activity in treatment-resistant models of colorectal and breast cancers.

Oral Milk Thistle Extract Stops Colorectal Cancer Stem Cells from Growing Tumors

4/21/2015 12:01 pm

(UCCC/In the Lab blog) Apr 20, 2015 - Results presented at AACR 2015 show that orally administering the chemical silibinin, purified from milk thistle, slows the ability of colorectal cancer stem cells to grow the disease.

Myriad and AstraZeneca Expand Research Collaboration on Lynparza

4/1/2015 05:21 pm

(MarketWatch) Apr 1, 2015 – In an expansion of its companion diagnostic collaboration with AstraZeneca, Myriad’s BRACAnalysis CDx test will be used to prospectively identify which patients with metastatic pancreatic cancer may respond to treatment with Lynparza™ (olaparib).

Myriad Announces Prolaris(R) Test Biopsy Results From EMPATHY-P Study at European Association of Urology Annual Meeting

3/20/2015 04:59 pm

(CNBC) Mar 20, 2015 - Myriad Genetics, Inc. today announced that results from the EMPATHY-P clinical study of Prolaris in patients newly diagnosed with prostate cancer will be highlighted at the 30th Annual Congress of the European Association of Urology.

ABRAXANE® Approved by European Commission for First-Line Treatment of Patients with Non-Small Cell Lung Cancer

3/2/2015 12:00 pm

(MarketWatch) Mar 2, 2015 - Celgene International Sàrl today announced that the European Commission (EC) has approved ABRAXANE® (paclitaxel formulated as albumin-bound nanoparticles, or nab-paclitaxel) in combination with carboplatin for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.

First Bladder Cancer Guideline to Reduce Variations in Care

2/26/2015 12:01 pm

(NICE) Feb 25, 2015 - NICE’s first guideline on bladder cancer aims to improve the diagnosis and management of the seventh most common cancer in the UK.

FDA Says It Knew Scopes That Allegedly Spread 'Superbug' Could Transmit Bacterial Infections

2/23/2015 12:02 pm

(ABC News) Feb 23, 2015 - The revelation that contaminated endoscopes were cleaned according to manufacturer instructions but still allegedly caused seven people to become infected with a deadly drug-resistant bacteria has raised questions about whether the scopes are too difficult to clean.

'Last Hope' Drug For Prostate Cancer Patients Is Axed From the NHS, in a Move Doctors Call a 'Travesty'

1/9/2015 11:03 am

(The Daily Mail [UK]) Jan 9, 2015 - A ‘last ditch’ drug for prostate cancer sufferers is to be axed from NHS use.

Specialists Split Over HPV Test's Role in Cancer Screening

1/8/2015 10:01 am

(NPR/Shots blog) Jan 8, 2015 - Two medical groups say doctors could replace the Pap smear with a different test to screen many women for cervical cancer.

Boehringer’s Vargatef Approved in the EU for Lung Cancer

12/1/2014 06:04 am

(PMLiVE [UK]) Nov 28, 2014 - The European Commission granted marketing authorisation for Vargatef (nintedanib) in combination with docetaxal for use in adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) after first-line chemotherapy.

Diagnostic Criteria Developed for Cancer-Linked Weight Loss

11/26/2014 10:01 am

(Doctors Lounge/HealthDay News) Nov 25, 2014 - A grading system has been developed for clinically important weight loss (WL) in patients with cancer, which includes the independent prognostic significance of body mass index (BMI) and percent WL, according to research published online Nov. 24 in the Journal of Clinical Oncology.